Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3...

Detaylı Bibliyografya
Asıl Yazarlar:	Clemens, SAC, Folegatti, PM, Emary, KRW, Weckx, LY, Ratcliff, J, Bibi, S, Verena De Almeida Mendes, A, Milan, EP, Pitella, A, Schwarzbold, AV, Sprinz, E, Aley, PK, Bonsall, D, Fraser, C, Fuskova, M, Gilbert, SC, Jenkin, D, Kelly, S, Kerridge, S, Lambe, T, Marchevsky, NG, Mujadidi, YF, Plested, E, Ramasamy, MN, Simmonds, P, Golubchik, T, Voysey, M, Pollard, AJ
Diğer Yazarlar:	AMPHEUS Project
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Springer Nature 2021

Benzer Materyaller

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Yazar:: Sue Ann Costa Clemens, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Yazar:: Emary, KRW, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Yazar:: Marchevsky, NG, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Yazar:: Natalie Gabrielle Marchevsky, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Yazar:: Voysey, M, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Yazar:: Voysey, M, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Yazar:: Frater, J, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
Yazar:: Hillson, K, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
Yazar:: Voysey, M, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
Yazar:: Md. Altamash Ahmad, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

A Systematic Review on the SARS CoV-2 Viral Vector Vaccine “Astrazeneca (Azd1222)”
Yazar:: rohama zahid, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
Yazar:: Li, G, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
Yazar:: Swanson, PA, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2
Yazar:: Pellegrino Cerino, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
Yazar:: Neeltje van Doremalen, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Hybrid Immunity in SARS-CoV-2: Are Antibody Responses Similar in all Infected and AZD1222 Vaccinated Persons?
Yazar:: Sajitha Musthafa, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters
Yazar:: Julia R. Port, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
Yazar:: Dharmendra S. Bhadauria, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
Yazar:: Jill Maaske, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

AZ arm: Delayed cutaneous reaction to ChAdOx1 nCoV-19 (AZD1222) vaccine
Yazar:: Wei-Kai Hung, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
Yazar:: Karina Soboleva, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
Yazar:: Watanabe, Y, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
Yazar:: Glenn A. Marsh, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Native-like SARS-CoV‑2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
Yazar:: Yasunori Watanabe, ve diğerleri
Baskı/Yayın Bilgisi: (2021-04-01)

Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
Yazar:: Ilir Alimehmeti
Baskı/Yayın Bilgisi: (2021-01-01)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
Yazar:: Jonathan D. Ho, MBBS, DSc, DipDermpath, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
Yazar:: Thomas Perkmann, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
Yazar:: Jayathilaka, D, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Cross-sectional evaluation of anti-SARS-CoV-2 antibody response to AZD1222 recombinant vaccine deployment in the Bono region, Ghana
Yazar:: Samuel Fosu Gyasi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Yazar:: David Benkeser, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
Yazar:: Janaína Jamile Ferreira Saraceno, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
Yazar:: Adam Abdullahi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination
Yazar:: Débora Familiar-Macedo, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
Yazar:: Magdalena E. Sobieszczyk, ve diğerleri
Baskı/Yayın Bilgisi: (2022-09-01)

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
Yazar:: Taylor S. Cohen, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2
Yazar:: Sang Won Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
Yazar:: Kaplonek, P, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle
Yazar:: Hyunji Choi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?
Yazar:: Vikas Deswal, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
Yazar:: Robert J. Fischer, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)